General
Preferred name
VERALIPRIDE
Synonyms
(¡À)-Veralipride ()
(±)-Veralipride ()
LIR166 ()
Agradil ()
Veraliprida ()
Agreal ()
P&D ID
PD014503
CAS
66644-81-3
Tags
available
drug
Drug Status
approved
withdrawn
experimental
Max Phase
4.0
Drug indication
Psychosis
First approval
1979
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION
Veralipride is a D2 receptor antagonist. It is an alternative antidopaminergic treatment for menopausal symptoms.
PRICE
180
DESCRIPTION
Veralipride ((??)-Veralipride) is an antagonist of D2 receptor.
DESCRIPTION
Veralipride ((±)-Veralipride) is an antagonist of D2 receptor.
(TargetMol Bioactive Compound Library)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Compound Sets
11
ChEMBL Approved Drugs
ChEMBL Drugs
DrugBank
DrugCentral
DrugCentral Approved Drugs
DrugMatrix
MedChem Express Bioactive Compound Library
NPC Screening Collection
ReFrame library
TargetMol Bioactive Compound Library
Withdrawn 2.0
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
23
Molecular Weight
383.15
Hydrogen Bond Acceptors
6
Hydrogen Bond Donors
2
Rotatable Bonds
8
Ring Count
2
Aromatic Ring Count
1
cLogP
0.73
TPSA
110.96
Fraction CSP3
0.47
Chiral centers
1.0
Largest ring
6.0
QED
0.64
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Target
D2
dopamine
Dopamine Receptor
ATC
N05AL06
Toxicity type
cardiovascular
Pathway
GPCR/G protein
Neuronal Signaling
Neuroscience
Source data
